Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Approves OZURDEX for Uveitis

September 29, 2010 7:15 am | News | Comments

Allergan, Inc. announced that the United States Food and Drug Administration has approved OZURDEX 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.

TOPICS:

Galapagos Starts Phase 2 Trial for RA

September 29, 2010 7:04 am | News | Comments

Galapagos NV announced that it has started a Phase 2 clinical study for the company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis.

TOPICS:

Fostamatinib Helpful in RA Patients

September 29, 2010 6:58 am | News | Comments

AstraZeneca’s oral syk inhibitor, fostamatinib, in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to methotrexate, according to recently published phase 2 study data.

TOPICS:
Advertisement

Movetis Begins Phase 3 Trial of Prucalopride

September 29, 2010 6:49 am | News | Comments

Movetis NV announces that it has started a phase 3 clinical trial with prucalopride in male patients with chronic constipation. Positive results from this clinical trial should allow Movetis to apply for expansion of the current label of Resolor.

TOPICS:

Depomed Receives Milestone Payment from Covidien

September 29, 2010 6:44 am | News | Comments

Depomed received a $500,000 payment from its partner Covidien PLC, which has started human testing of an extended-release painkiller using its technology.

TOPICS:

XOMA Completes Enrollment of Phase 2 Diabetes Trial

September 29, 2010 6:39 am | News | Comments

XOMA Ltd. announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes. XOMA 052 is a therapeutic antibody candidate that inhibits the inflammatory cytokine interleukin-1 beta.

TOPICS:

Protein Expression

September 28, 2010 8:52 am | Product Releases | Comments

AMSBIO has announced Solu BL21 Competent E. coli, a significantly improved BL21 host strain for soluble mammalian protein expression.

TOPICS:

Mass Spectrometer

September 28, 2010 8:50 am | Product Releases | Comments

The AB SCIEX TripleTOF 5600 System is a fast and sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.

TOPICS:
Advertisement

Microplate Mixer

September 28, 2010 8:46 am | Product Releases | Comments

Microsonic Systems has announced that its HENDRIX SM100 now serves four key applications: Compound solubilization, Sample thawing, Microplate mixing, and Magnetic particles/cells suspension.

TOPICS:

GATC Biotech Plans to Sequence 100k Genomes By 2015

September 28, 2010 8:30 am | News | Comments

Within the next four years GATC Biotech plans to analyse 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research.

TOPICS:

Walgreen Income Up 8%

September 28, 2010 8:28 am | News | Comments

Walgreen Co., the largest drugstore chain in the U.S., said its net income rose 8 percent in the fiscal fourth quarter on higher prescription drug sales.

TOPICS:

Chelsea Therapeutics Beginning RA Drug Trial

September 28, 2010 8:22 am | News | Comments

Chelsea Therapeutics International, Ltd. has initiated enrollment in a Phase 2 trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate in patients with rheumatoid arthritis who are experiencing an inadequate response to methotrexate.

TOPICS:

Cytheris Registering Patients for INSPIRE 3

September 28, 2010 8:18 am | News | Comments

Cytheris SA announced that it has begun enrolling patients in a Phase 2 clinical trial evaluating the effect of repeated cycles of CYT107 in HIV-1 infected patients classified as immunological non-responders after at least 24 months of HAART.

TOPICS:

Wider Statin Use Could Cut Costs in Long Run

September 28, 2010 7:47 am | News | Comments

A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke.

TOPICS:

SNPs Lead to Painful Aromatase Inhibitor Side Effects

September 28, 2010 7:44 am | News | Comments

Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading